Lars Schröder1, Bernd Pötzsch, Heiko Rühl, Ulrich Gembruch, Waltraut M Merz. 1. Institute for Experimental Hematology and Transfusion Medicine, the Department of Obstetrics and Gynecology and Center for Integrated Oncology (CIO) Cologne/Bonn, and the Department of Obstetrics and Prenatal Medicine, University Bonn, Bonn, Germany.
Abstract
BACKGROUND: Complications of conservative management of abnormal placentation in which the placenta is left in situ for resorption include secondary hemorrhage, infection, and disseminated intravascular coagulation. CASE: A 41-year old woman received conservative treatment for placenta percreta. Nine weeks after delivery, she developed gingival bleeding, easy bruising, and moderate-to-severe vaginal bleeding. Hemostasis testing established the diagnosis of isolated hyperfibrinolysis; acute disseminated intravascular coagulation was excluded. Bleeding was successfully treated using the antifibrinolytic agent tranexamic acid. Eight weeks later uncomplicated curettage was performed. CONCLUSION: Isolated hyperfibrinolysis is a potential cause of bleeding during conservative management of placenta increta and percreta. Management of this treatment approach should include hemostasis monitoring, because hyperfibrinolysis can be successfully controlled using fibrinolysis inhibitors.
BACKGROUND: Complications of conservative management of abnormal placentation in which the placenta is left in situ for resorption include secondary hemorrhage, infection, and disseminated intravascular coagulation. CASE: A 41-year old woman received conservative treatment for placenta percreta. Nine weeks after delivery, she developed gingival bleeding, easy bruising, and moderate-to-severe vaginal bleeding. Hemostasis testing established the diagnosis of isolated hyperfibrinolysis; acute disseminated intravascular coagulation was excluded. Bleeding was successfully treated using the antifibrinolytic agent tranexamic acid. Eight weeks later uncomplicated curettage was performed. CONCLUSION: Isolated hyperfibrinolysis is a potential cause of bleeding during conservative management of placenta increta and percreta. Management of this treatment approach should include hemostasis monitoring, because hyperfibrinolysis can be successfully controlled using fibrinolysis inhibitors.
Authors: C Biele; L Kaufner; A Schwickert; A Nonnenmacher; K von Weizsäcker; M Z Muallem; W Henrich; T Braun Journal: Arch Gynecol Obstet Date: 2020-08-18 Impact factor: 2.344
Authors: C Biele; L Kaufner; A Nonnenmacher; K von Weizsäcker; M Z Muallem; W Henrich; Thorsten Braun Journal: Arch Gynecol Obstet Date: 2021-02-05 Impact factor: 2.344